Cargando…

Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma

PURPOSE: As a continuation of our search for anticancer agents, we have synthesized a new acridine-retrotuftsin analog HClx9-[Arg(NO(2))-Pro-Lys-Thr-OCH(3)]-1-nitroacridine (named ART) and have evaluated its activity against melanoma and neuroblastoma lines. Both tumors develop from cells (melanocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Cichorek, Miroslawa, Ronowska, Anna, Gensicka-Kowalewska, Monika, Deptula, Milena, Pelikant-Malecka, Iwona, Dzierzbicka, Krystyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326014/
https://www.ncbi.nlm.nih.gov/pubmed/30367436
http://dx.doi.org/10.1007/s00432-018-2776-4
_version_ 1783386228482113536
author Cichorek, Miroslawa
Ronowska, Anna
Gensicka-Kowalewska, Monika
Deptula, Milena
Pelikant-Malecka, Iwona
Dzierzbicka, Krystyna
author_facet Cichorek, Miroslawa
Ronowska, Anna
Gensicka-Kowalewska, Monika
Deptula, Milena
Pelikant-Malecka, Iwona
Dzierzbicka, Krystyna
author_sort Cichorek, Miroslawa
collection PubMed
description PURPOSE: As a continuation of our search for anticancer agents, we have synthesized a new acridine-retrotuftsin analog HClx9-[Arg(NO(2))-Pro-Lys-Thr-OCH(3)]-1-nitroacridine (named ART) and have evaluated its activity against melanoma and neuroblastoma lines. Both tumors develop from cells (melanocytes, neurons) of neuroectodermal origin, and both are tumors with high heterogeneity and unsatisfactory susceptibility to chemotherapies. Thus, we analyzed the action of ART on pairs of biological forms of melanoma (amelanotic and melanotic) and neuroblastoma (dopaminergic and cholinergic) with regard to proliferation, mechanism of cell death, and effect on the activity of tricarboxylic acid cycle (TAC) enzymes. METHODS: The cytotoxicity of ART was evaluated by XTT and trypan blue tests. Cell death was estimated by plasma membrane structure changes (phosphatidylserine and calreticulin externalization), caspase activation, presence of ROS (reactive oxygen species), activity of tricarboxylic acid cycle enzymes (pyruvate dehydrogenase complex, aconitase, and isocitrate dehydrogenase), NAD level, and ATP level. RESULTS: ART influences the biological forms of melanoma and neuroblastoma in different ways. Amelanotic (Ab) melanoma (with the inhibited melanogenesis, higher malignancy) and SHSY5Y neuroblastoma (with cholinergic DC cells) were especially sensitive to ART action. The Ab melanoma cells died through apoptosis, while, with SH-SY5Y-DC neuroblastoma, the number of cells decreased but not as a result of apoptosis. With Ab melanoma and SH-SY5Y-DC cells, a diminished activity of TAC enzymes was noticed, along with ATP/NAD depletion. CONCLUSION: Our data show that the biological forms of certain tumors responded in different ways to the action of ART. As a combination of retrotuftsin and acridine, the compound can be an inducer of apoptotic cell death of melanoma, especially the amelanotic form. Although the mechanism of the interrelationships between energy metabolism and cell death is not fully understood, interference of ART with TAC enzymes could encourage the further investigation of its anticancer action. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-018-2776-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6326014
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-63260142019-01-23 Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma Cichorek, Miroslawa Ronowska, Anna Gensicka-Kowalewska, Monika Deptula, Milena Pelikant-Malecka, Iwona Dzierzbicka, Krystyna J Cancer Res Clin Oncol Original Article – Cancer Research PURPOSE: As a continuation of our search for anticancer agents, we have synthesized a new acridine-retrotuftsin analog HClx9-[Arg(NO(2))-Pro-Lys-Thr-OCH(3)]-1-nitroacridine (named ART) and have evaluated its activity against melanoma and neuroblastoma lines. Both tumors develop from cells (melanocytes, neurons) of neuroectodermal origin, and both are tumors with high heterogeneity and unsatisfactory susceptibility to chemotherapies. Thus, we analyzed the action of ART on pairs of biological forms of melanoma (amelanotic and melanotic) and neuroblastoma (dopaminergic and cholinergic) with regard to proliferation, mechanism of cell death, and effect on the activity of tricarboxylic acid cycle (TAC) enzymes. METHODS: The cytotoxicity of ART was evaluated by XTT and trypan blue tests. Cell death was estimated by plasma membrane structure changes (phosphatidylserine and calreticulin externalization), caspase activation, presence of ROS (reactive oxygen species), activity of tricarboxylic acid cycle enzymes (pyruvate dehydrogenase complex, aconitase, and isocitrate dehydrogenase), NAD level, and ATP level. RESULTS: ART influences the biological forms of melanoma and neuroblastoma in different ways. Amelanotic (Ab) melanoma (with the inhibited melanogenesis, higher malignancy) and SHSY5Y neuroblastoma (with cholinergic DC cells) were especially sensitive to ART action. The Ab melanoma cells died through apoptosis, while, with SH-SY5Y-DC neuroblastoma, the number of cells decreased but not as a result of apoptosis. With Ab melanoma and SH-SY5Y-DC cells, a diminished activity of TAC enzymes was noticed, along with ATP/NAD depletion. CONCLUSION: Our data show that the biological forms of certain tumors responded in different ways to the action of ART. As a combination of retrotuftsin and acridine, the compound can be an inducer of apoptotic cell death of melanoma, especially the amelanotic form. Although the mechanism of the interrelationships between energy metabolism and cell death is not fully understood, interference of ART with TAC enzymes could encourage the further investigation of its anticancer action. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-018-2776-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-10-26 2019 /pmc/articles/PMC6326014/ /pubmed/30367436 http://dx.doi.org/10.1007/s00432-018-2776-4 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article – Cancer Research
Cichorek, Miroslawa
Ronowska, Anna
Gensicka-Kowalewska, Monika
Deptula, Milena
Pelikant-Malecka, Iwona
Dzierzbicka, Krystyna
Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title_full Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title_fullStr Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title_full_unstemmed Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title_short Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
title_sort novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
topic Original Article – Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326014/
https://www.ncbi.nlm.nih.gov/pubmed/30367436
http://dx.doi.org/10.1007/s00432-018-2776-4
work_keys_str_mv AT cichorekmiroslawa noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma
AT ronowskaanna noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma
AT gensickakowalewskamonika noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma
AT deptulamilena noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma
AT pelikantmaleckaiwona noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma
AT dzierzbickakrystyna noveltherapeuticcompoundacridineretrotuftsinactiononbiologicalformsofmelanomaandneuroblastoma